686 related articles for article (PubMed ID: 35671157)
1. PROTACs: past, present and future.
Li K; Crews CM
Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
[TBL] [Abstract][Full Text] [Related]
2. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
3. Recent advancements in the discovery of cereblon-based protease-targeted chimeras with potential for therapeutic intervention.
Singh H; Agrawal DK
Future Med Chem; 2022 Oct; 14(19):1403-1416. PubMed ID: 36047364
[TBL] [Abstract][Full Text] [Related]
4. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
[TBL] [Abstract][Full Text] [Related]
5. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
Chaudhry C
J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
[TBL] [Abstract][Full Text] [Related]
6. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Pettersson M; Crews CM
Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
[TBL] [Abstract][Full Text] [Related]
7. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
8. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
9. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
10. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications.
Li Q; Zhou L; Qin S; Huang Z; Li B; Liu R; Yang M; Nice EC; Zhu H; Huang C
Eur J Med Chem; 2023 Sep; 257():115447. PubMed ID: 37229829
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in PROTACs for Drug Targeted Protein Research.
Yao T; Xiao H; Wang H; Xu X
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142231
[TBL] [Abstract][Full Text] [Related]
12. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
13. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
14. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
15. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs.
Maneiro M; De Vita E; Conole D; Kounde CS; Zhang Q; Tate EW
Prog Med Chem; 2021; 60():67-190. PubMed ID: 34147206
[TBL] [Abstract][Full Text] [Related]
16. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
17. The rise of covalent proteolysis targeting chimeras.
Gabizon R; London N
Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
[TBL] [Abstract][Full Text] [Related]
18. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
19. PROTAC-DB 2.0: an updated database of PROTACs.
Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
[TBL] [Abstract][Full Text] [Related]
20. Chemically induced degradation of epigenetic targets.
Kabir M; Yu X; Kaniskan HÜ; Jin J
Chem Soc Rev; 2023 Jul; 52(13):4313-4342. PubMed ID: 37314393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]